{"id":"NCT04732949","sponsor":"Synairgen Research Ltd.","briefTitle":"Study to Assess Efficacy and Safety of Inhaled Interferon-Î² Therapy for COVID-19","officialTitle":"A Randomised, Double-blind, Placebo-controlled, Phase III Trial to Determine the Efficacy and Safety of Inhaled SNG001 for the Treatment of Patients Hospitalised Due to Moderate COVID-19","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-01-12","primaryCompletion":"2021-12-15","completion":"2022-02-10","firstPosted":"2021-02-01","resultsPosted":"2023-03-27","lastUpdate":"2023-03-27"},"enrollment":623,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Severe Acute Respiratory Syndrome Coronavirus 2","COVID-19"],"interventions":[{"type":"DRUG","name":"SNG001","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"SNG001","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this Phase III study is to confirm that SNG001 can accelerate the recovery of hospitalised patients receiving oxygen with confirmed Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Safety and other efficacy endpoints will also be assessed.","primaryOutcome":{"measure":"Time to Hospital Discharge","timeFrame":"Day 28","effectByArm":[{"arm":"SNG001","deltaMin":7,"sd":null},{"arm":"Placebo","deltaMin":8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.509"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":11},"locations":{"siteCount":112,"countries":["United States","Argentina","Belgium","Brazil","Colombia","France","Germany","India","Israel","Italy","Mexico","Netherlands","Portugal","Romania","Serbia","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":38,"n":301},"commonTop":["Productive cough","Headache","Myalgia","Rhinorrhoea","Arthralgia"]}}